Practical treatment context

Evidence-Based Options

For people researching ibogaine, established treatments offer a different path: options evaluated in clinical research, used in real-world care, and reflected in major health guidance.

A grounded comparison

Established care has more than one route.

For an overview of the wider questions people bring to this topic, the main ibogaine alternatives guide places evidence, safety, legality, and practical questions alongside each other. On this page, the focus is narrower: treatments clinicians and people who use substances commonly choose instead of ibogaine.

“Evidence-based” does not mean guaranteed. It means an approach has been studied, its limits are part of the conversation, and major guideline bodies can weigh the available evidence. Treatment decisions remain personal and should involve qualified professional guidance.

01

Opioid use disorder

Methadone, buprenorphine, and extended-release naltrexone are established medication options. They are used with different treatment goals, including withdrawal suppression, craving reduction, and relapse prevention.

  • Methadone is commonly provided through regulated treatment programs.
  • Buprenorphine is often available in outpatient care.
  • Extended-release naltrexone is a non-opioid medication option.
02

Alcohol use disorder

Naltrexone, acamprosate, and disulfiram are among the established medication options for alcohol use disorder. They have different intended roles and are generally considered alongside a person’s goals, health context, and behavioral support.

  • Craving reduction may be one treatment aim.
  • Relapse prevention can be another.
  • Outpatient care is a common setting for ongoing support.
03

Stimulant use disorder

For stimulant use disorder, behavioral approaches are central. Contingency management and other behavioral therapies have a substantial place in the evidence base, while medication treatment is less established than it is for opioid use disorder.

  • Contingency management uses structured incentives.
  • Behavioral therapies can target patterns around use.
  • Care may take place in outpatient or residential settings.
Warm clinical setting illustrating structured treatment options and ongoing support

Opioid use disorder

Medication options can serve distinct goals.

Methadone and buprenorphine are used to support treatment for opioid use disorder and may address withdrawal suppression and cravings. Extended-release naltrexone is another established option, generally discussed in relation to a person’s treatment goals and readiness for that approach.

The World Health Organization guidance on opioid dependence treatment describes methadone and buprenorphine as key pharmacological approaches. In the United States, the FDA’s overview of medication-assisted treatment also identifies approved medication pathways for opioid dependence.

Typical settings vary. Buprenorphine may be part of office-based outpatient care; methadone is commonly delivered through regulated programs; and residential care may be considered when a person needs a more structured environment. These are not interchangeable routes, and randomized controlled trial evidence is interpreted alongside real-world access, continuity, and individual circumstances.

“The useful comparison is not one treatment against another in the abstract, but which evidence-supported path fits the substance, the goal, and the setting.”

Alcohol use disorder

Medication and support can be paired.

Naltrexone, acamprosate, and disulfiram are established medications used in treatment for alcohol use disorder. They are not identical: their expected role, practical fit, and the questions a clinician may consider differ. Some people use medication alongside counseling or other behavioral support, while treatment plans vary across outpatient, clinic-based, and residential settings.

The evidence base includes randomized controlled trials as well as broader syntheses of research. The Cochrane review of acamprosate and naltrexone evaluates these medications for alcohol dependence, helping frame both the usefulness and limits of the research literature.

For someone considering ibogaine in relation to alcohol use, this comparison matters because established options are designed around familiar treatment goals: reducing cravings, supporting abstinence or reduced use where appropriate, and helping prevent return to problematic patterns. A treatment plan does not need to be a single intervention to be coherent.

Stimulants & behavioral care

Behavioral therapies remain central for stimulant use disorder.

Contingency management is a structured behavioral approach that uses incentives tied to agreed treatment targets. It has been studied for stimulant use disorder and is often discussed alongside other behavioral therapies. The CDC’s treatment information for substance use disorders notes the role of evidence-based treatment and behavioral health support across substance use concerns.

Care may be outpatient, clinic-based, or residential depending on the person’s needs and circumstances. For people researching ibogaine, it is important not to assume that a treatment model for one substance will transfer neatly to another.

Which goals can established treatment address?

Depending on the approach and substance involved, established treatment may address withdrawal suppression, craving reduction, relapse prevention, and behavioral patterns linked with continued use. The appropriate goals and setting vary by person and should be discussed with qualified care.

Are behavioral therapies used alongside medication?

They often are. Behavioral therapies can be used with medication for opioid or alcohol use disorder, and they are central evidence-based options for stimulant use disorder, including contingency management.

What does evidence-based mean here?

It refers to treatments evaluated through clinical research and reflected in guidance from major health authorities. Evidence strength, expected outcomes, and individual suitability differ by treatment and by substance use disorder.

Where are these options usually provided?

Many services are outpatient, while methadone is commonly dispensed through regulated programs. Residential care may be used when a person’s needs, safety, or living situation call for a more structured setting.

Keep the frame clear

Evidence is one part of an informed ibogaine decision.

For treatment context around ibogaine, information about ibogaine clinics in Mexico may be relevant to what people encounter in their research, while established treatment options should be assessed on their own evidence and practical terms.

How we approach uncertainty